COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office
PTAB rejects two requests for rehearing of the USPTO’s decision denying institution of post-grant review…
Year: 2023
COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office
PTAB rejects two requests for rehearing of the USPTO’s decision denying institution of post-grant review…
Enlivex to Present at the 2023 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage…
Enlivex to Present at the 2023 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage…
Madrigal Pharmaceuticals Supports International NASH Day on June 8
Company expands support for NASH disease education through patient advocacy partnerships and a new digital…
Madrigal Pharmaceuticals Supports International NASH Day on June 8
Company expands support for NASH disease education through patient advocacy partnerships and a new digital…
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome…
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome…
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a…
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a…
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
– Financing led by Atlas Venture and Forbion – Company created, incubated and seed financed by Sofinnova…
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
– Financing led by Atlas Venture and Forbion – Company created, incubated and seed financed by Sofinnova…
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchange Positive…
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchange Positive…
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading…
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading…
Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline…
Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline…